TABLE 2.

Adverse drug reactions by time of onset in the safety analysis set (n = 17)

Adverse drug reaction	Onset of adverse drug reaction (weeks)
	Study 001		Study 002
	0–24	25–48	49–72	73–96	97–120	121–144	145–168	≥169
N	17	17	17	14	13	13	10	4
Pale feces	4 (23.5)	2 (11.8)	1 (5.9)	0	0	0	0	0
Flatulence	3 (17.6)	0	0	0	0	0	0	0
Injection site induration	2 (11.8)	4 (23.5)	4 (23.5)	1 (7.1)	1 (7.7)	1 (7.7)	1 (10.0)	1 (25.0)
Malaise	2 (11.8)	0	0	0	0	0	0	0
Abdominal distension	2 (11.8)	0	0	0	0	0	0	0
Diabetes mellitus	2 (11.8)	1 (5.9)	0	0	0	0	0	0
Injection site pruritus	1 (5.9)	0	0	0	0	0	0	0
Pyrexia	1 (5.9)	0	0	0	0	0	0	0
Abdominal pain	1 (5.9)	1 (5.9)	0	0	0	0	0	0
Diarrhea	1 (5.9)	1 (5.9)	0	0	0	0	0	0
Dental caries	1 (5.9)	0	0	0	0	0	0	0
Gingival bleeding	1 (5.9)	0	0	0	0	0	0	0
Nausea	1 (5.9)	0	0	0	0	0	0	0
Stomatitis	1 (5.9)	0	0	0	0	0	0	0
Impaired glucose tolerance	1 (5.9)	0	0	1 (7.1)	0	0	0	0
T2DM	1 (5.9)	0	0	0	0	0	0	0
Cholelithiasis	1 (5.9)	0	0	0	0	1 (7.7)	0	0
Hepatic steatosis	1 (5.9)	0	0	0	0	0	0	0
Increased ALT levels	1 (5.9)	1 (5.9)	1 (5.9)	0	0	0	0	0
Increased AST levels	1 (5.9)	1 (5.9)	1 (5.9)	0	0	0	0	0
Bronchopneumonia	1 (5.9)	0	0	0	0	0	0	0
Herpes zoster infection	1 (5.9)	0	0	0	0	0	0	0
Pharyngitis	1 (5.9)	0	0	0	0	0	0	0
Dizziness	1 (5.9)	0	0	0	0	0	0	0
Injection site pain	0	1 (5.9)	1 (5.9)	0	0	0	0	0
Upper abdominal pain	0	0	0	0	1 (7.7)	0	0	0
Pancreatitis	0	1 (5.9)	0	0	0	0	0	0
Hyperglycemia	0	1 (5.9)	0	0	0	0	0	0
Bile duct stone	0	1 (5.9)	0	0	1 (7.7)	0	0	0
Urticaria	0	0	1 (5.9)	0	0	0	0	0

Data are shown as n (%).

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; T2DM, type 2 diabetes mellitus.